2020
DOI: 10.1016/j.ijantimicag.2020.106019
|View full text |Cite
|
Sign up to set email alerts
|

Co-occurrence of aminoglycoside and β-lactam resistance mechanisms in aminoglycoside- non-susceptible Escherichia coli isolated in the Zurich area, Switzerland

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

2
34
0

Year Published

2020
2020
2024
2024

Publication Types

Select...
7
1

Relationship

1
7

Authors

Journals

citations
Cited by 29 publications
(41 citation statements)
references
References 39 publications
2
34
0
Order By: Relevance
“…The variations in results of the prevalent ESBL types might be attributed to differences in sampling period and geographical locations (Vital et al 2018). Aminoglycosides are antibiotics that are frequently used in combination with β-lactams for the treatment of gram-negative bacterial infections (Bodendoerfer et al 2020). One mechanism of resistance of aminoglycosides involves the formation of enzymes, which modify the antibiotic drug at various sites (Bodendoerfer et al 2020;Schaenzer & Wright 2020).…”
Section: Resultsmentioning
confidence: 99%
See 1 more Smart Citation
“…The variations in results of the prevalent ESBL types might be attributed to differences in sampling period and geographical locations (Vital et al 2018). Aminoglycosides are antibiotics that are frequently used in combination with β-lactams for the treatment of gram-negative bacterial infections (Bodendoerfer et al 2020). One mechanism of resistance of aminoglycosides involves the formation of enzymes, which modify the antibiotic drug at various sites (Bodendoerfer et al 2020;Schaenzer & Wright 2020).…”
Section: Resultsmentioning
confidence: 99%
“…Aminoglycosides are antibiotics that are frequently used in combination with β-lactams for the treatment of gram-negative bacterial infections (Bodendoerfer et al 2020). One mechanism of resistance of aminoglycosides involves the formation of enzymes, which modify the antibiotic drug at various sites (Bodendoerfer et al 2020;Schaenzer & Wright 2020). The strA gene is one of the resistance genes that encode aminoglycoside-modifying enzyme, which confers resistance to streptomycin (Frye & Jackson 2013;Poirel et al 2018).…”
Section: Resultsmentioning
confidence: 99%
“…In contrast, susceptibility to standard-of-care aminoglycosides was lower, at <97% and <79%, respectively, when based on RMTase gene annotations alone and not taking into account the high number of aminoglycoside-modifying enzymes that inactivate the various standard-of-care aminoglycosides but not apramycin. The higher levels of aminoglycoside resistance in CP isolates might not be surprising, given the frequent co-occurrence of different resistance genes, including that of RMTases with carbapenemases [ 6 , 30 , 31 , 32 ]. Of note, we did not detect any aac(3)-IV genes in the critical pathogen populations of carbapenem-resistant A. baumannii and Pseudomonas aeruginosa .…”
Section: Discussionmentioning
confidence: 99%
“…Furthermore, 76 strains (63.3%; 76/120) carried bla OXA−1 and eight (6.7%; 8/120) bla CTX−M−27 . Previous studies reported the co-occurrence of bla CTX−M−15 and bla OXA−1 , whereas other members of the CTX-M family (e.g., bla CTX−M−27 ) and bla OXA−1 appear to be mutually exclusive (Schaufler et al, 2016b;Livermore et al, 2019;Bodendoerfer et al, 2020). Here, almost all strains carrying the bla OXA−1 gene (98.7%; 75/76) carried the bla CTX−M−15 gene in addition and none showed the combination of bla OXA−1 and another CTX-M gene.…”
Section: Antimicrobial Resistance Determinantsmentioning
confidence: 96%